glp-1 medication shortage Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s GLP-1 use: More people without
Description
These early exits from therapy not only undermine clinical outcomes but also distort commercial forecasts and ROI projections
Same-week appointments, transparent cash-pay rates for plans still in credentialing, telehealth from day one.
Only 40% of 2023 initiators remained on therapy after a year compared to 34% of 2022 initiators and 33% of 2021 initiators
The clinical results so far are hard to ignore
GLP-1 is reshaping the household grocery cart
Each capsule is enteric-coated to help safeguard probiotics as they pass through the stomach, ensuring optimal delivery to the GI tract
